✕
Not registered yet? Please contact our project manager Sonja Leissner . This area is only for members of the research consortium.
✕

PANcreatic CAncer Initial Detection via liquid biopsy

Stay informed on the project!

News
3 July 2026

PANCAID Co-Coordinator Matthias Löhr Receives Lifetime Achievement Award

The PANCAID consortium warmly congratulates our co-coordinator, Prof. Matthias Löhr (Karolinska Institutet), on receiving the Lifetime Achievement Award at the joint European Pancreatic Club (EPC) / International Association of Pancreatology (IAP) Meeting. The award recognises Prof. Löhr's longstanding contributions to pancreatic cancer research and his commitment to advancing the field over many years. As co-coordinator...
Read more
News
05 May 2026

PANCAID issues lab-SOP for prospective blood collection

Harmonised workflows are crucial for coordinated sample collection and initial processing. This is especially important if multiple biospecimen types from the same patient are collected. We published a set of lab-SOPs on Figshare that describe the workflow for collecting the following sample types from the same patients: Plasma separation Whole blood handling Dried blood spots...
Read more
Event
11 June 2026

PANCAID’s 8th Steering Committee Meeting

Earlier this week, PANCAID's Steering Committee met fully virtually for its 8th Steering Committee Meeting to review project progress, discuss ongoing activities, and align on priorities for the coming months. With 3.5 years of the project already completed, partners reflected on the significant progress achieved so far and outlined an ambitious roadmap for the final...
Read more
View all news

About

PANCAID is an international research consortium aiming to develop a minimally invasive blood test using liquid biopsy to detect pancreatic cancer to facilitate early detection of the cancer and its precursors. With 20 members from eight countries, the project has received funding for five years to potentially revolutionize current pancreatic cancer diagnosis methods and improve patient outcomes.

Learn More

Our vision

PANCAID strives to provide a minimally invasive blood test using a comprehensive panel of liquid biopsy diagnostics (LBx) for early detection of pancreatic cancer and its precursor lesions.

Read on

Why it matters

Pancreatic cancer is a malignant neoplasm that originates in the cells of the pancreas, an organ located in the abdominal cavity behind the stomach. It is known to be one of the most aggressive and deadly types of cancer, with a high mortality rate. Pancreatic cancer is often difficult to detect in its early stages, as it tends to show minimal or no symptoms until it reaches advanced stages. This makes it challenging to diagnose and treat, and contributes to its poor prognosis.

Discover more